Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207311 · ClinicalTrials.gov registry record · Phase 4
Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
A Phase 4 study, sponsored by Brooke Army Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00207311 is a Phase 4 study that has completed, run by Brooke Army Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT00207311, a Phase 4 study, has completed, sponsored by Brooke Army Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, randomized, placebo-controlled trial in subjects with histological evidence of \> 33% hepatic steatosis or nonalcoholic steatohepatitis (NASH) and chronic hepatitis C. Patients who have not been previously treated for hepatitis C (treatment naive) will be enrolled.
Interventions
- DRUG Xenical, Pegasys, Copegus
- BEHAVIORAL Xenicare Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207311
The ClinicalTrials.gov registry entry for NCT00207311 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brooke Army Medical Center, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Xenical, Pegasys, Copegus is the first listed.
NCT00207311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207311 about?
NCT00207311 is a clinical study titled "Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus". This is a prospective, multi-center, randomized, placebo-controlled trial in subjects with histological evidence of \> 33% hepatic steatosis or nonalcoholic steatohepatitis (NASH) and chronic hepatitis C. Patients who have not been previously treated for hepatitis C (treatment naive) will be enrolle...
What is the current status of trial NCT00207311?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2005-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00207311?
The interventions under investigation include: Xenical, Pegasys, Copegus (DRUG), Xenicare Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00207311?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.